Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Two New R&D Heads: The Fit Is "Extraordinary”

This article was originally published in The Pink Sheet Daily

Executive Summary

In their first joint interview since announcing the new leadership structure of a bulked-up Pfizer, Martin Mackay and Mikael Dolsten, speak candidly about their R&D initiatives.
Advertisement

Related Content

Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less
Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less
Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less
Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less
Pfizer Selects Sites for its Post-Merger Global R&D Network
Pfizer Selects Sites for its Post-Merger Global R&D Network
Pfizer Drafts A New “Org Chart” Post Wyeth Merger
Pfizer Drafts A New “Org Chart” Post Wyeth Merger
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion

Topics

Advertisement
UsernamePublicRestriction

Register

PS069399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel